News | Heart Failure | October 06, 2022

Cleveland Clinic-Led Trial Finds That Increasing Salt Intake Does Not Affect Patients Hospitalized with Congestive Heart Failure During Treatment

Results presented at the Heart Failure Society of America Annual Scientific Meeting

Results presented at the Heart Failure Society of America Annual Scientific Meeting

October 6, 2022 —  Findings from a Cleveland Clinic-led trial show that increasing the salt intake by mouth for patients who are hospitalized with heart failure undergoing aggressive diuretic therapy did not affect how much fluid they retain or their kidney function, indicating that salt intake for heart failure patients may not be as harmful as previously thought. Conversely, these new findings may challenge the common practice of salt restriction during hospital admission since that might not be as helpful. 

Findings from the “Oral Sodium to Preserve Renal Efficiency In Acute Heart Failure (OSPREY-AHF): A Single-center, Double-Blind, Randomized, Placebo-controlled Trial” were presented during a late-breaking clinical trial session at the Heart Failure Society of America Annual Scientific Meeting by Dr. Robert Montgomery, Advanced Heart Failure/Transplant Fellow from Cleveland Clinic’s Kaufman Center for Heart Failure Treatment and Recovery

“Since the 1940s we've been taught that salt is the main reason why people become congested with fluid, which led to the idea that we need to keep people low on salt while in the hospital with fluid overload,” said senior author W. H. Wilson Tang, MD, cardiologist in the Section of Heart Failure and Cardiac Transplantation Medicine in the Heart, Vascular & Thoracic Institute at Cleveland Clinic. 

“There have even been some reports of potential benefits of infusing salt to facilitate more urination with high-dose diuretic drugs in patients with congestive heart failure.  However, our study did not show such benefits with raising oral salt supplementation and gave us an indication that keeping a low-salt diet during aggressive diuretic therapy may not be as effective as we thought.” 

Heart failure is a condition in which the heart is not always able to pump enough blood for the body’s needs. It affects nearly six million people in the United States. Heart failure is a common cause of hospital readmissions and the leading cause of hospitalization for people over 65 years of age.  Most heart failure patients admitted to the hospital experience congestive symptoms such as swelling and shortness of breath from fluid build-up in the lungs. 

According to the U.S. Centers for Disease Control and Prevention, an average American diet contains about 4 grams of salt per day. Typically, patients with heart failure admitted to the hospital are restricted to a low salt diet (about 2 grams per day). 

In the trial, the first double-blinded, placebo-controlled randomized clinical trial to study this, a total of 65 patients were enrolled and analyzed between June and July 2022. Thirty-one patients were assigned to placebo and 34 patients were assigned to the salt (or sodium chloride) intervention. 

When compared to placebo, the addition of up to 6 grams of salt per day -- 2 grams given three times daily during intravenous diuretic therapy -- did not lead to a statistically significant difference in weight change or kidney function at 96 hours or earlier discharge. 

There were no statistically significant differences in all clinical or laboratory measures except for less fluctuations in some laboratory measurements in the oral salt intervention group compared to the placebo group. 

 “Our findings do not mean that patients with heart failure should start eating more salt, as we only studied the role of oral salt supplementation in those receiving high-dose diuretic drugs during their hospitalizations.” adds Dr. Tang. “Patients with heart failure still need to be mindful that excessive salt intake may cause fluid congestion.” 

The OSPREY-AHF trial was funded by the Cleveland Clinic Heart Vascular and Thoracic Institute’s Wilson Grant and the Kaufman Center for Heart Failure Treatment and Recovery Grant. 

For more information: http://www.clevelandclinic.org/ 

Related Content: 

Cutting Salt Intake Shows Some Benefits for People with Heart Failure 

Good Hydration May Reduce Long-term Risks for Heart Failure 

Spotlight on Heart Disease Prevention Pioneer, Jeremiah Stamler, MD 


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now